top of page

We had over 100 abstract submissions for the EHRS2023 meeting. You can see all abstracts in full if you click on the link above.


You can find the list of abstracts selected for poster presentation, and their assigned number below.  If your poster is an even number, stand by it for presentation on Wednesday 14th and Friday 16th. If your poster is an odd number, stand by it for presentation on Thursday 15th and Friday 16th.

Posters should be A1 size and in portrait orientation.


- We highly recommend printing on fabric using Scienceposters. They have a special EHRS rate of £30 if you book through the dedicated meeting website:

- The posters will be delivered straight to the venue and attached to your designated poster board before your arrival. The Deadline for this service is Wednesday 7th June.

- Alternatively, please print and bring your poster with you when you register on the first day of the conference.

List of Posters

  1. A long journey to a safe, affordable and effective injectable treatment for alopecia areata

  2. A retrospective study on the clinical characteristics and prognosis of alopecia totalis and universalis : an update on prognosis

  3. Case series of alopecia areata in inflammatory bowel disease patients

  4. Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey

  5. The Contribution of Hair Regrowth to Health-Related Quality of Life Improvements in Patients with Alopecia Areata Treated with Baricitinib or Placebo

  6. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Results from BRAVE-AA1 and BRAVE AA-2

  7. Scalp Hair Regrowth is Associated with Improvements in Health-Related Quality of Life (HRQoL) and Psychological Symptoms in Patients with Severe Alopecia Areata: Results from Two Randomized Controlled Trials

  8. Long-term Efficacy of Baricitinib in Alopecia Areata: 104-week Results from BRAVE-AA1 and BRAVE AA-2

  9. Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4-mg: Week 104 Data from BRAVE AA-2

  10. The role of inflammasome in alopecia areata

  11. A Clinical Investigation of Early-Onset Alopecia Areata in Children: onset earlier than 4 years of age might have a better prognosis

  12. Real-world effectiveness and safety of baricitinib in patients with alopecia areata

  13. Efficacy of calcipotriol/betamethasone ointment in management of pediatric alopecia areata

  14. Clinical efficacy and safety of baricitinib for alopecia areata in Korea: single centre experience

  15. Recurrent episodes of alopecia totalis post COVID-19 vaccination

  16. Evaluation of the early efficacy and safety of JAK inhibitors in patients with refractory severe Alopecia Areata

  17. Markers of Th2 in alopecia areata and their correlations to allergy, atopy and longer disease duration

  18. Risk of subclinical atherosclerosis in severe alopecia areata patients

  19. Efficacy of topical immunotherapy with 2,3-Diphenylcyclopropenone-1(DPCP) in patients with extensive Alopecia Areata. Twenty years of experience from the Hair Diseases Department of “Andreas Syggros” Hospital, Athens, Greece.

  20. Alopecia Areata Totalis treated with phytotherapy and intradermotherapy with results similar to JAK inhibitors

  21. Dermoscopy findings of the axilla of women with frontal fibrosing alopecia

  22. Immersive VR : an adjunctive measure to improve quality of life in chemotherapy induced alopecia

  23. The involvement of the scalp and nail apparatus in cutaneous lupus erythematosus patients: A retrospective study

  24. Efficacy of oral retinoids as a maintenance therapy in cicatricial alopecia: a retrospective study

  25. Minoxidil-induced trichostasis spinulosa of vellus hair?

  26. Do statins have a role in treating Frontal Fibrosing Alopecia?

  27. A case of male frontal fibrosing alopecia after COVID-19 vaccination

  28. Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia

  29. 3D camera imaging of Frontal Fibrosing Alopecia: a novel assessment method

  30. Lichen planopilaris in women with Afro-textured hair

  31. Frontal fibrosing alopecia in South Africa: a questionnaire study

  32. Seasonal hair loss in Northern and Southern Hemispheres: Insights from Google Trends data

  33. Interest of a Cinchona succirubra extract and its association with Caffeine in hair loss

  34. Molecular monitoring of transcriptional effects following treatment of male volunteers with commencing hair loss after treatment with an extract of Quassia Amara Wood containing serum

  35. Trichoscopic findings after hair transplant with FUE technique

  36. Scalp analysis with Multiparametric Ultrasound before and after application of cosmetic with vasoconstrictor active

  37. Pitfalls in alopecia photography.

  38. Scalp flora plays a role in the hair regrowth effect of topical minoxidil.

  39. Scalp interactome, what impact does a new treatment shampoo have on the ecosystem of the scalp with seborrheic dermatitis? Focus on flaking, inflammation and pruritus.

  40. Targeting inflammation and specialized pro-resolving mediators: a new pathway to improve scalp condition?

  41. Quantifying Particle Deposition on Hair by Streaming Potential

  42. Is the fatigue and failure resistance of hair dependent on ethnic origin?

  43. Evolution of hair measurements for clinical outcomes: Are they reliable?

  44. Effect of particulate matter on hair disease

  45. Effect of ethnicity, temperature, and humidity on the viscoelastic behaviour of human hair fibres, and the associated structural changes identified with FT-IR microscopy

  46. Transcriptomics to uncover the role of the dermal papilla in human hair fibre pigmentation

  47. Impact of topical application of anti-dementia agents on hair growth

  48. Mapping HIF1a and ARNT to cell states and identities in cycling human hair follicle: the keratinocyte fate in the “adaptive signaling landscape”

  49. Unveiling the trichogenic signature of the human native dermal papilla

  50. Activation of mitochondrial aldehyde dehydrogenase 2 promotes hair growth

  51. Noncontact compression promotes hair growth through vasodilation

  52. Revealling the anagen prolonging effects of a ginger extract by means of different in vitro and ex vivo hair follicle models

  53. Wnt ligand expression diversity during mouse hair follicle development.

  54. Using in vitro and ex vivo culture models to study the ability of cooling to suppress oxidative stress-mediated, chemotherapy drug-induced alopecia

  55. The role of T-helper 17 cells and regulatory T cells in acute diffuse and total alopecia

  56. A concept for the molecular monitoring of transcriptional effects of hair growth stimulating serums

  57. High throughput screening in vitro assays for the identification of drug candidates inhibiting immune privilege collapse in alopecia areata

  58. Optimized Hidradenitis Suppurativa skin organ culture as preclinical research platform

  59. Ex vivo evaluation of the hydration capacity of a new haircare product and its active ingredient based on cactus extract by using the method of Nuclear Magnetic Resonance (NMR)

  60. The investigation of clinical characteristics of male patients diagnosed with early-onset androgenetic alopecia: a possible association with metabolic syndrome

  61. Efficacy and safety of dutasteride 0.2mg in male androgenic alopecia patients: a multi-center, randomized, double-blinded, placebo-controlled, parallel group, phase III clinical trial

  62. Hi-C 3D Genomic Interactions confirm role of Wnt in Androgenetic Alopecia

  63. Eye Movement Desensitisation and Reprocessing Therapy (EMDR) in the management of Alopecia Areata (AA)

  64. The percentage of online consultation increased from 15% to 40% after the COVID-19 pandemic.

  65. “There's a sense of losing yourself and who you are”: Development of a conceptual model via literature and interviews points to large psychosocial burden and lower health-related quality of life for UK-based alopecia patients with ≥50% hair loss.

  66. The socioeconomic burden of Alopecia Areata

  67. The importance of trichoscopy in psychotrichologic disorders

  68. Successful treatment of trichotillomania with habit reversal therapy in a child.

  69. Unsupervised Self-sourced Medication for Alopecia: The Tip of the Iceberg?

bottom of page